literature

SARS_CoV_2 mutation literature information.

Whole Genome Sequencing of SARS-CoV-2 Strains in COVID-19 Patients From Djibouti Shows Novel Mutations and Clades Replacing Over Time.

PMID: 34540874 2021 Frontiers in medicine

Table: E484K

Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants.

PMID: 34543625 2021 The Journal of biological chemistry

Table: E484K

Figure: A double mutant (E484K/N501Y) and triple mutants corresponding to Beta variant (K417N/E484K/N501Y) and Gamma variant (K417T/E484K/N501Y) were also used.

Figure: Panels A-I show the data for the wild-type RBD, single amino acid mutations K417N, Y453F, S477N, T478I, E484K, S494P, N501Y, and for the triple mutant K417T/

PMID: 34544043 2021 The American journal of tropical medicine and hygiene

Conclusion: It was recently reported that there are four major epitope classes on the SARS-CoV-2 spike protein receptor-binding domain where neutralizing antibodies bind, and that Q493R (BV-1) and E484K (not found in BV-1, but important in B.1.351 and B.1.617 variants) mediate roughly equivalent levels of resistance to only class-2 neutralizing antibodies, as defined in that study.

Review of the mechanisms of SARS-CoV-2 evolution and transmission.

PMID: 34545334 2021 ArXiv

Abstract: We predict that RBD co-mutation [A411S, L452R, T478K], [L452R, T478K, N501Y], [L452R, T478K, E484K, N501Y], [K417N, L452R, T478K], and [P384L, K417N, E484K, N501Y] will have high chances to grow into dominating variants due to their high infectivity and/or strong ability to break through current vaccines, calling for the development of new vaccines and antib

Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display.

PMID: 34545362 2021 bioRxiv

Abstract: A potent ACE2-blocking nAb was further engineered to sustain binding to S RBD with the E484K and L452R substitutions found in multiple SARS-CoV-2 variants.

SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels.

PMID: 34545803 2021 Emerging infectious diseases

Abstract: While conducting genomic surveillance (1,663 cases) from December 2020-April 2021 in Arizona, USA, we detected an emergent E484K-harboring variant, B.1.243.1.

Introduction: E484K variants have also been identified in reinfection cases, suggesting a role in breakthrough infections; these findings indicate the need to monitor for SARS-CoV-2 variants in real time.

Introduction: Genomic sequencing of SARS-CoV-2 E484K variant B.1.243.1, Arizona, USA.

Introduction: In contrast, the 2 additional B.1.243 cases bearing the E484K mutation alone were phylogenetically distinct from the B.1.243.1 clade, suggesting that those isolates had evolved independently.

Introduction: Several of these VOCs and VOIs (e.g., Beta/B.1.351, Gamma/P.1, Delta/B.1.617.2) harbor the E484K mutation in the

PMID: 34547629 2021 Biochemical and biophysical research communications

Method: Mutant RBDs (K417T/E484K/N501Y, L452R/T478K, and L452R) were purchased from Sino Biological.

Method: Pseudoviruses for Gamma, Delta, Epsilon, Kappa, L452R, T478K, and P681H, K417T, E484K, and N501Y were produced.

Result: E484K (8.66-fold) and N501Y (5.49-fold) was less than 10-fold susceptible to CT-P59, but CT-P59 showed lower IC50 value (0.7-fold) against K417T

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.

PMID: 34549975 2021 Journal of virology

Result: We assessed neutralization activ

Result: mRNA-1273-elicited neutralization titers against B.1.1.7, B.1.1.7+E484K, B.1.427/B.1.429, P.1, and B.1.351-v1 observed herein corroborated previous findings.

Table: E484K

SARS-CoV-2 B.1.1.7 lineage rapidly spreads and replaces R.1 lineage in Japan: Serial and stationary observation in a community.

PMID: 34560289 2021 Infection, genetics and evolution

Abstract: After the emerging of the R.1 lineage harboring E484K variant (designated VOI in Japan), the prevalent B.1.1.214 lineage were no longer identified.

Introduction: We previously reported on the SARS-CoV-2 R.1 lineage harboring spike W152L, E484K and G769V mutations.

Table: E484K

Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients.

PMID: 34561414 2021 Signal transduction and targeted therapy

Discussion: The K417N+E484K+N501Y triple mutant in the B.1.351 variant significantly reduces the neutralizing activity of convalescent and post-vaccination sera.

Browser Board

Co-occurred Entities

Filtrator